Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2004 Sep-Oct;19(5):269-74.
doi: 10.1177/153331750401900502.

Why do many NMDA antagonists fail, while others are safe and effective at blocking excitotoxicity associated with dementia and acute injury?

Benedict C Albensi  1 , Chiazor Igoechi, Damir Janigro, Erin Ilkanich
Affiliations
Review

Why do many NMDA antagonists fail, while others are safe and effective at blocking excitotoxicity associated with dementia and acute injury?

Benedict C Albensi et al. Am J Alzheimers Dis Other Demen. 2004 Sep-Oct.

Abstract

Similar to drug development programs for stroke and traumatic brain injury, programs developed for Alzheimer's disease (AD) have not been very effective in treating dementia. Recently, researchers have explored modulating excitatory synaptic neurotransmission via the N-methyl-D-aspartate receptor (NMDAR) to treat AD. However, many investigators doubt that NMDA antagonists are safe and effective for treating persons with AD because they have failed in stroke and trauma programs. This article explores the role of NMDA-mediated excitotoxicity in AD, reviews how the NMDAR functions, highlights the side effects and alternate signaling pathways that are initiated from NMDAR activation, provides examples of NMDA antagonists that do not exhibit the typical side effects, and discusses why some NMDA antagonist compounds are effective and safe in limiting cascades of excitotoxicity in dementia or acute brain injury.

PubMed Disclaimer

References

    1. Ikonomidou C, Turski L: Why did NMDA receptor antagonists fail clinical trials for stroke and traumatic brain injury? Lancet Neurol. 2002; 1(6): 383-386. - PubMed
    1. Roesler R, Quevedo J, Schroder N: Is it time to conclude that NMDA antagonists have failed? Lancet Neurol.2003; 2(1): 13-13. - PubMed
    1. Smith PF: Therapeutic N-methyl-D-aspartate receptor antagonists: Will reality meet expectation? Curr Opin Investig Drugs.2003; 4(7): 826-832. - PubMed
    1. Scarpini E, Scheltens P, Feldman H: Treatment of Alzheimer's disease: Current status and new perspectives. Lancet Neurol.2003; 2(9): 539-547. - PubMed
    1. van Reekum R, Black SE, Conn D, et al.: Cognition-enhancing drugs in dementia: A guide to the near future. Can J Psychiatry.1997; 42(Suppl 1): 35S-50S. - PubMed

MeSH terms